Anethole attenuates lung cancer progression by regulating the proliferation and apoptosis through AKT and STAT3 signaling
Abstract
Background: The main constituent of fennel, anethole, exerts beneficial effects in many diseases, including antiproliferative and tumoricidal capacities. This study aimed to investigate the effect of anethole on the human non-small cell lung cancer (NSCLC) cell line, A549, and the related molecular mechanisms.
Methods: The proliferation was assessed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and colony formation assays. Apoptosis situation was determined using fluorescence-activated cell sorting and DNA fragmentation assay combined with immunoblotting assay probing-related protein expression. Phosphoinositide 3-kinases-protein kinase B (PI3K-AKT) and signal transducer and activator of transcription 3 (STAT3) signaling proteins were evaluated using immunoblotting. Xenograft model was constructed to determine the tumor volume and weight and to evaluate the expression of Ki67 via immunohistochemistry and cleaved caspase 3 via immunoblotting.
Results: Anethole inhibited proliferation and clonal growth of A549 cells. The promotion of A549 cell apoptosis by anethole was evidenced by increased apoptotic ratio, abundant DNA fragments, and caspase-3 activation. Key proteins in PI3K-AKT and STAT3 signaling pathways were decreased in anethole group. Additionally, xenografted tumors in anethole group retarded with decreased Ki67 and increased cleaved caspase 3 expression.
Conclusions: Anethole induced tumor cell apoptosis and retarded cell proliferation. AKT and STAT3 signaling pathways might be involved in the effects of anethole. Our findings highlight the feasibility of anethole in the treatment of lung cancer.
Downloads
References
Sharma P, Mehta M, Dhanjal DS, Kaur S, Gupta G, Singh H, et al. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chem Biol Interact. 2019; 309: 108720. doi: 10.1016/j.cbi.2019.06.033
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30. doi: 10.3322/caac.21590
Malyla V, Paudel KR, Shukla SD, Donovan C, Wadhwa R, Pickles S, et al. Recent advances in experimental animal models of lung cancer. Future Med Chem. 2020; 12(7): 567–70. doi: 10.4155/fmc-2019-0338
Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014; 40(8): 990–1004. doi: 10.1016/j.ctrv.2014.05.009
Klastersky J, Awada A. Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol. 2012; 81(1): 49–57. doi: 10.1016/j.critrevonc.2011.02.002
Islam KM, Anggondowati T, Deviany PE, Ryan JE, Fetrick A, Bagenda D, et al. Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer. BMC Cancer. 2019; 19(1): 835. doi: 10.1186/s12885-019-6054-x
Peng Z, Wu WW, Yi P. The efficacy of ginsenoside Rg3 combined with first-line chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials. Front Pharmacol. 2020; 11: 630825. doi: 10.3389/fphar.2020.630825
von Plessen C. Improving chemotherapy for patients with advanced non-small cell lung cancer. Clin Respir J. 2011; 5(1): 60–1. doi: 10.1111/j.1752-699X.2010.00199.x
Aprotosoaie AC, Costache, II, Miron A. Anethole and its role in chronic diseases. Adv Exp Med Biol. 2016; 929: 247–67. doi: 10.1007/978-3-319-41342-6_11
Chen CH, deGraffenried LA. Anethole suppressed cell survival and induced apoptosis in human breast cancer cells independent of estrogen receptor status. Phytomedicine. 2012; 19(8–9): 763–7. doi: 10.1016/j.phymed.2012.02.017
Elkady AI. Anethole inhibits the proliferation of human prostate cancer cells via induction of cell cycle arrest and apoptosis. Anticancer Agents Med Chem. 2018; 18(2): 216–36. doi: 10.2174/1871520617666170725165717
Chainy GB, Manna SK, Chaturvedi MM, Aggarwal BB. Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB, AP-1, JNK, MAPKK and apoptosis. Oncogene. 2000; 19(25): 2943–50. doi: 10.1038/sj.onc.1203614
Choo EJ, Rhee YH, Jeong SJ, Lee HJ, Kim HS, Ko HS, et al. Anethole exerts antimetatstaic activity via inhibition of matrix metalloproteinase 2/9 and AKT/mitogen-activated kinase/nuclear factor kappa B signaling pathways. Biol Pharm Bull. 2011; 34(1): 41–6. doi: 10.1248/bpb.34.41
Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am. 2019; 103(3): 463–73. doi: 10.1016/j.mcna.2018.12.006
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689): 446–54. doi: 10.1038/nature25183
Wanigasooriya K, Tyler R, Barros-Silva JD, Sinha Y, Ismail T, Beggs AD. Radiosensitising cancer using phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKT) or mammalian target of rapamycin (mTOR) inhibitors. Cancers (Basel). 2020; 12(5): 1278. doi: 10.3390/cancers12051278
Lee YJ, Kim WI, Park TH, Bae JH, Nam HS, Cho SW, et al. Upregulation of DJ-1 expression in melanoma regulates PTEN/AKT pathway for cell survival and migration. Arch Dermatol Res. 2021; 313(7): 583–591. doi: 10.1007/s00403-020-02139-1
Xiao S, Li S, Yuan Z, Zhou L. Pyrroline-5-carboxylate reductase 1 (PYCR1) upregulation contributes to gastric cancer progression and indicates poor survival outcome. Ann Transl Med. 2020; 8(15): 937. doi: 10.21037/atm-19-4402
John L, Krauth MT, Podar K, Raab MS. Pathway-directed therapy in multiple myeloma. Cancers (Basel). 2021; 13(7): 1668. doi: 10.3390/cancers13071668
Yu H, Tian L, Yang L, Liu S, Wang S, Gong J. Knockdown of SNORA47 inhibits the tumorigenesis of NSCLC via mediation of PI3K/Akt signaling pathway. Front Oncol. 2021; 11: 620213. doi: 10.3389/fonc.2021.620213
Song M, Bode AM, Dong Z, Lee MH. AKT as a Therapeutic target for cancer. Cancer Res. 2019; 79(6): 1019–31. doi: 10.1158/0008-5472.CAN-18-2738
Darnell JE, Jr. The JAK-STAT pathway: summary of initial studies and recent advances. Recent Prog Horm Res. 1996; 51: 391–403; discussion 4.
Gao P, Niu N, Wei T, Tozawa H, Chen X, Zhang C, et al. The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis. Oncotarget. 2017; 8(40): 69139–61. doi: 10.18632/oncotarget.19932
Schaefer LK, Ren Z, Fuller GN, Schaefer TS. Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene. 2002; 21(13): 2058–65. doi: 10.1038/sj.onc.1205263
Li S, Priceman SJ, Xin H, Zhang W, Deng J, Liu Y, et al. Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One. 2013; 8(12): e81657. doi: 10.1371/journal.pone.0081657
Lee H, Jeong AJ, Ye SK. Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep. 2019; 52(7): 415–23. doi: 10.5483/BMBRep.2019.52.7.152
Song D, Lan J, Chen Y, Liu A, Wu Q, Zhao C, et al. NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein. Oncogene. 2021; 40(16): 2952–67. doi: 10.1038/s41388-021-01747-z
Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding Q, et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J Exp Clin Cancer Res. 2019; 38(1): 149. doi: 10.1186/s13046-019-1161-8
Rhee YH, Chung PS, Kim SH, Ahn JC. CXCR4 and PTEN are involved in the anti-metastatic regulation of anethole in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2014; 447(4): 557–62. doi: 10.1016/j.bbrc.2014.01.121
Ha B, Ko H, Kim B, Sohn EJ, Jung JH, Kim JS, et al. Regulation of crosstalk between epithelial to mesenchymal transition molecules and MMP-9 mediates the antimetastatic activity of anethole in DU145 prostate cancer cells. J Nat Prod. 2014; 77(1): 63–9. doi: 10.1021/np4006376
Copyright (c) 2023 Venkata Kumar, Maddula Venkateswarulu
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain full copyright to their individual works, and publishing rights without restrictions.
In accordance with the Budapest Open Access Initiative, articles published in STEMedicine are freely available "on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited."
Except where otherwise noted, all content on this website is licensed under a Creative Commons Attribution 4.0 License. This license allows for commercial and non-commercial redistribution as well as modifications of the work as long as attribution is given to the authors and STEMedicine as the original publication source, and a link to the article on the STEMedicine website is provided.
